公开(公告)号：EP3954711A1

公开(公告)日：2022-02-16

申请号：EP20788397.6

申请日：2020-04-06

申请人： Green Cross Corporation ,  Mogam Institute for Biomedical Research

发明人： PARK, Jae Chan ,  SONG, Eun Jung ,  LIM, So Jung ,  LEE, Jae-Chul ,  KWON, Hae Naem ,  LEE, Su A ,  LIM, Ok Jae ,  KIM, Mun Kyung ,  CHO, Hyun Jung ,  KIM, Gil-Jung ,  LEE, Jee Won ,  KIM, Sung Keun ,  WON, Jong Wha ,  JANG, Shin A

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61P35/00

摘要： The present invention relates to a bispecific anti-GPNMB/anti-CD3 antibody specifically binding to CD3 and GPNMB, and the use thereof. Particularly, the bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.

公开(公告)号：EP3699199A2

公开(公告)日：2020-08-26

申请号：EP18868854.3

申请日：2018-10-22

申请人： Green Cross Corporation ,  Mogam Institute for Biomedical Research

发明人： KIM, Ki Su ,  JEONG, Jun Hong ,  KIM, Dong Sik ,  LIM, Yang Mi ,  PARK, Yong Yea ,  LIM, Hyung Kwon ,  WON, Jong Wha

IPC分类号： C07K16/30

摘要： The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.